INTRODUCTION
Neuroblastoma, the most common solid tumour of childhood, is an embryonal tumour of the postganglionic sympathetic nervous system. The most common genetic features of NB are amplification of the proto-oncogene MYCN, deletions of parts of chromosome arms 1p and 11q, gain of parts of 17q and triploidy. MYCN amplification, 1p loss and 17q gain are strongly associated with aggressive tumours and a poor outcome for the patient, whereas triploidy is associated with low-stage neuroblastomas with a good outcome [1] [2] [3] .
ALK (OMIM 105590) is dominantly expressed in the neural system and the gene encoding it is located on the short arm of chromosome 2 (2p23.2) [4, 5] . It is a tyrosine kinase that was first identified as part of a fusion gene between NPM (nucleophosmin) and ALK, which is the result of the translocation t(2;5)(p23;q35) in anaplastic large cell lymphoma [6, 7] . The ALK kinase is constitutively activated by the gene amplification of ALK in three neuroblastoma cell lines and it has been shown that the suppression of activated ALK induces apoptosis through reduced phosphorylation of ShcC, mitogen-activated protein kinases and Akt [8] . The ALK locus has previously been reported to be amplified in single cases of primary neuroblastoma tumours with MYCN amplification [8] [9] [10] [11] [12] . In a recent study by Mosse et al., ALK was identified as a major familial neuroblastoma predisposition gene with activating germline mutations mapping to the TKD [13] . They also detected ALK amplifications in sporadic tumours mainly of metastatic stage and with poor outcome and ALK mutations in a subset of high-risk neuroblastoma [13] . We recently performed a CGH array study of 92 NB tumors [14] and detected a few cases of amplification of the ALK gene in chromosome region 2p that was distinct from the amplification of MYCN (also in 2p but distal of the ALK gene). These data together with the recent finding by Mosse et al. prompted us to perform this detailed study of ALK gene copy number, amplification, rearrangement and mutation as well as expression patterns of ALK and related genes in sporadic childhood neuroblastoma tumours of all clinical stages. A panel of 90 primary NB tumours of all clinical stages according to the International  Neuroblastoma Staging System, INSS, 11 stage 1, 12 stage 2, 13 stage 3 , 46 stage 4, four stage 4S and four tumours of unknown stage from children without known familial history of neuroblastoma, was used for mutation analysis. In addition, normal tissue (blood samples) from some of the patients with identified mutations was used. Genomic DNA was extracted with a DNeasy blood and tissue kit (Qiagen, Hilden, Germany) according to the protocol provided by the supplier. RNA from 19 of the tumours used for mutation analysis was extracted from collected tumour material after homogenisation by TissueLyser (Qiagen), using the Totally RNA kit (Ambion, St. Austin, TX). Genomic DNA was removed with the DNA-free kit (Ambion) and the purity and integrity of the RNA samples were assayed with the ND-1000 spectrophotometer (NanoDrop, Wilmington, DE ) and RNA 6000 Nano Bioanalyzer (Agilent, Palo Alto, CA) respectively. Seventy of the tumours used for mutation screening have also been analysed with SNP arrays, together with 38 additional tumours; this material has been described previously [14] . Informed consent was obtained from the patients' parents and the study was approved by the relevant ethics committees.
EXPERIMENTAL

Patient and control material
SNP microarray analysis
The DNA microarray experiments have been described previously [14] . Briefly, Affymetrix 250K arrays were used and primary data analysis was performed using GDAS software (Affymetrix, Inc., Santa Clara, CA), while further statistical studies were performed using CNAG (Copy Number Analyzer for Affymetrix GeneChip Mapping arrays) software, version 3.0 (GenomeLaboratory, Tokyo University, http://www.genome.umin.jp) [15, 16] .
DNA amplification and sequencing
Primers were designed for exons and flanking intronic sequences of the TKD and surrounding exons of the ALK transcript (uc002rmy.1/ NM_004304 from UCSC Genome Browser March 2006; exons 20-26). Primers were designed using the Exonprimer feature of the UCSC genome browser (URL: http://genome.ucsc.edu/) and primers were ordered from Invitrogen (Invitrogen, Carlsbad, CA). Touch-down PCR was performed in 10µl reactions containing 1X Coral Load PCR Buffer (Qiagen), 0.2mM dNTP mix, 0.25U Hot Star TaqPlus DNA polymerase (Qiagen), 10µM of forward and reverse primer respectively and 25ng of tumour DNA. The PCR program was performed as follows: 95°C for five minutes before cycling 20 rounds of 95°C for 30 sec, 65°C for 30 sec (decreasing 0.5°C in every cycle) and 72°C for one minute -followed by 20 cycles of 95°C for 30 sec, 55°C for 30 sec and 72°C for one minute and finally a 72°C extension step for seven minutes. The specificity of products was inspected by agarose gel electrophoresis before they were purified using Agencourt AMPure magnetic beads (Beckman Coulter, Beverly, MA) using the Biomek NX pipetting robot (Beckman Coulter) and eluted in dH 2 O.
Sequence PCR was performed using the BigDye Terminator (BDT) v3.1 Cycle Sequence Kit (Applied Biosystems) in 10µl reactions containing 6µl 1:3 diluted PCR-template DNA, 1µl BDT, 1X BDT buffer and 1.6µM of forward or reverse PCR primer. Sequence PCR was run under the following conditions: 94°C for three minutes, followed by 50 cycles of 96°C for 30 sec, 50°C for 10 sec and 60°C for three minutes each. Sequencing products were purified using CleanSeq magnetic beads (Agencourt) using the Biomek NX and re-suspended in 10µl of High Dye formamide (Applied Biosystems). The sequencing products were separated with gel electrophoresis on an 3730 DNA analyser (Applied Biosystems) and the output data were viewed and analysed using SeqScape v 2.5 (Applied Biosystems). All the fragments were analysed with both forward and reverse primer and all the findings were confirmed by sequencing a new PCR product.
Expression microarray analysis
Microarray expression analysis from 19 tumours including samples without ALK gene aberrations and samples with ALK gene rearrangement, amplification and mutation of the TKD was performed using the HU133A and HU133plus2 expression arrays from Affymetrix (www.affymetrix.com). Expression analysis of the five tumour cases, NB56, NB18, NB41, NB42 and NB30, was performed on HU133A chips as described previously (Wilzén et al., 2008, submitted), whereas the remaining 14 tumour cases were analysed by the HU133plus2 platform at Aros AB (www.arosab.com, unpublished data). The total RNA samples used for the HU133A chips were labelled according to standard procedures from Affymetrix, whereas the total RNA samples used for the HU133plus2 analysis were labelled using the NuGEN whole transcriptome amplification WT-Ovation™ FFPE System (www.nugenic.com).
The downstream genes assumed to be positively regulated by ALK were selected from Bohling et al. [17] . Gene profiles from two fusion gene experiments (TPM3-ALK and NPM-ALK) were compared, and ALK-specific downstream targets were identified. In the current study, we chose the eight most up-regulted genes from these expression profiles; BCL10, CEBPB, INHBA, IL2RB, COL6A3, TNC, IL1R1, and FCGR3A/FCGR3B, to represent the ALK-pathway activation. A Pearson correlation calculation was performed on our expression data from these eight genes, and they were found to correlate well. To add up the total activation of the ALK downstream pathway, the mean of the log2 expression value from the eight genes was calculated and then raised to the power of 2. 
RESULTS
SNP array analysis
Four tumours harboured amplification of the ALK gene and one tumour showed a rearrangement inside ALK, see Figure 1 . In addition, ALK was amplified in the IMR-32 NB cell line. All cases with amplification also showed amplification of MYCN. A gain of chromosome 2p was detected in 20 cases; 18 of these included the ALK gene and five showed MYCN amplification, see Figure 2 . Moreover, five NB cell lines showed a gain of chromosome 2p; two of them also had an amplification of MYCN. It should be noted that cell line SH-SY-5Y is derived from cell line SK-N-SH, and as expected they showed identical 2p-gain.
DNA sequencing
Five different missense mutations in a total of 10 tumours were detected in the TKD, see Table 1 . In exon 20 (outside the TKD), at base 3182, a G>A substitution was detected in one NB tumour. This resulted in an amino acid change from arginine to a glutamine. At positions 3520 and 3522, the mutations T>A (one tumour) and C>A (three tumours), respectively, were detected, both changing the amino acid phenylalanine into isoleucine and leucine respectively ( Figure 3 ). Two novel mutations, 3733T>A and 3735C>A (not previously published), were detected in exon 24, giving rise to an amino acid change from phenylalanine to isoleucine and leucine, in one tumour each. In four NB tumours, a mutation was detected at position 3824 (G>A), resulting in the transition from the amino acid arginine to glutamine. In addition, one silent change (3633C>A) was found in three tumours and one non-coding (IVS22+18 C>T) was detected in five tumours.
Expression analysis
Gene expression of ALK was analysed in 19 NB tumours by DNA microarrays, see Figure 4 . The highest expression was detected in the three unfavourable tumours; NB29, NB42 and NB30 harbouring ALK mutation and amplifications, respectively. In addition, eight ALKdownstream positively regulated transcripts were analysed ( Figure 4 ) and their expression levels correlated significantly (p<0.01) with one another according to Pearson's correlation test (data not shown). Results from six tumours, NB21, NB56, NB18, NB41, NB42, and NB30 indicate activation of both ALK and the ALK downstream pathway.
DISCUSSION
The ALK gene has been shown to be involved in several chromosomal translocations or inversions contributing to oncogenesis and providing a putative therapeutic target in several different tumour types, reviewed by Chiarle et al. [18] . The most common is the translocation t(2;5)(p23;q35) in anaplastic large cell lymphomas that gives rise to the oncogenic NPM-ALK fusion protein. Fusion proteins involving ALK and other partner proteins have also been identified in diffuse large B-cell lymphomas and inflammatory myofibroblastic tumours [19, 20] .
From our study and recent data on neuroblastoma it is suggested that ALK is activated and may contribute to tumour development also through gene amplification and specific mutations targeting the TKD as indicated by elevated expression of ALK and downstream genes and constitutive kinase phosphorylation [13] . In a recent study, screening various molecular targeted inhibitors in a large panel of cell lines, it was found that a selective inhibitor of ALK, TAE684, potently suppresses the growth of a subset of neuroblastoma cell lines and the authors suggest that neuroblastoma tumours with ALK amplification or rearrangements may be responsive to treatment with ALK kinase inhibition [21] . ALK is therefore an attractive target for novel therapeutic strategies in neuroblastoma and it is noteworthy that several ALK kinase inhibitors are in development for specific targeted cancer therapy including early clinical testing [22] .
In a recent study using array CGH of 92 NB primary tumours, we identified rare cases with ALK amplification. In this study we more thoroughly investigated the frequency of ALK abnormalities in neuroblastoma using data from the array CGH, expression arrays and DNA sequencing. In our study, the first to investigate both mutations and copy number alterations in a large set of sporadic NB tumours of all clinical stages and different biological subsets, we detected ALK aberrations in a subset of advanced tumours from children with unfavourable outcome. ALK amplification and intragenic re-arrangements were detected in five tumours (Figure 1) , giving a frequency of chromosomal abnormalities of 4.6% (5/108) with 3.7% being amplifications, close to the 3.3% amplification rate in sporadic cases recently published [13] . In addition, a previously not reported amplification of ALK was also detected in the IMR-32 NB cell line. Eighteen additional tumours harboured a gain of chromosome 2p that included ALK (16.7% compared to 22.8% as previously reported [13] ), see Figure 2 . Five of them also had an amplification of the MYCN gene. The gene target of the 2p gain in NB tumours is not known. Both MYCN and/or ALK are potent targets that could contribute to transformation when involving extra copies. In this context, it is interesting to note that 18 of 20 2p gain cases contain ALK in the gain region.
Mosse et al. sequenced the coding exons of ALK in NB and reported alterations in the TKD of ALK in familial neuroblastoma and in high-risk sporadic NB tumours [13] . In the present study, we also focused on the TKD and surrounding exons and sequenced them in 90 NB tumours. Mutations resulting in amino acid changes were found in 11 cases (10 located in the TKD), see Table 1 . Three of the mutations in the TKD have been reported previously and they have a predicted high probability of resulting in oncogenic activation [13] , while two have not been described previously. Interestingly, they target the same amino acid as one of the mutations previously reported, phenylalanine at amino acid position 1245. The frequency of amino acid substitutions in the TKD was 11.1% in our material of tumours from all clinical stages compared with 12.4% in high-risk tumours as investigated by Mosse et al. Counting DNA mutations inside the TKD and chromosomal abnormalities gives a frequency of 16% of tumours where ALK is affected in the present study (2p gain cases not included). Interestingly, although investigating the full spectrum of NB tumours, ALK activating gene aberrations were only detected in advanced tumours either metastatic or with big primaries (large or unresectable stage 2 or 3 according to the INSS) including several with extensive tumour growth into the spinal canal (data not shown). Children with small localised tumours available for radical surgery never showed either mutations in the TKD, ALK amplifications or unbalanced 2p gain (p=0.002, Fisher's exact test). Furthermore, ALK aberrations correlated significantly with unfavourable outcome with inferior survival probability of 33%, 50% and 52% for children with TKD mutations, amplifications and 2p gain, respectively. However, all children dying from disease had additional unfavourable clinical and biological prognostic features, apart from ALK alterations. One patient, (harbouring the F1245I mutation; Table 1 ) with extensive regional residual tumour without known adverse prognostic factors, is a long term survivor despite absence of therapy for remaining viable tumour tissue. The clinical role of ALK mutations still seems unclear since both among familial cases [13] and in our material of sporadic tumours there are several long-term survivors indicating that ALK mutations is not an adverse factor per se.
The expression analysis agrees well with the data on gene amplification and DNA mutations. The three tumours with the highest expression of ALK had either ALK amplification (two cases), or a mutation (F1245L; one case; Figure 4 ). Moreover, high ALK expression appears to up-regulate ALK downstream targets, although the re-arrangement in tumour NB10 does not appear to affect the expression of ALK, and it only slightly affects downstream genes. Moreover, the F1245L mutation found in case NB29 does not appear to affect the ALK downstream targets selected in this study. This may be explained by the mutation-specific activation of selected downstream pathways. Also, the eight selected targets (see experimental section) probably do not cover all downstream effects of ALK. We should also bear in mind that we did not include analysis of ALK protein expression or phosphorylation status. Interestingly, there are four cases (NB21, NB56, NB18 and NB41) that both show high ALK expression and indicate strong downstream activation, but with no detectable ALK amplification or mutation. These cases will be the subject of further detailed mutation and rearrangement studies of ALK.
In conclusion, we have analysed chromosomal re-arrangements of the ALK gene, performed a mutation screening of the ALK TKD and investigated the expression of ALK and related genes in a large number of sporadic NB primary tumours from all clinical and biological subsets. We present two novel mutations in the TKD of ALK. ALK mutations were found in 11% of NB tumours and gene amplification or re-arrangements were found in 5%. DNA mutations and gene amplifications generally showed a correlation with the expression level of ALK and downstream genes of ALK and unfavourable clinical features like extensive primary tumours or metastatic stage and poor prognosis. The data presented here and those previously published by Mosse et al. [13] provide clear evidence that ALK plays an important role in a significant fraction of advanced sporadic NB tumours as well as in the small number of cases with familial tumours. These studies also open new options for specific targeted therapy in children with neuroblastoma. A c c e p t e d M a n u s c r i p t Licenced copy. Copying is not permitted, except with prior permission and as allowed by law. A c c e p t e d M a n u s c r i p t Licenced copy. Copying is not permitted, except with prior permission and as allowed by law. A c c e p t e d M a n u s c r i p t Licenced copy. Copying is not permitted, except with prior permission and as allowed by law.
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